Although it was difficult to analyze the long-term prognosis with data reflecting the rapidly changing trend of HER2-positive breast cancer therapy, it was possible to infer factors affecting breast cancer specifically in HER2-positive breast cancer, by comparing the OS with the same period. This evidence concerns the gene ERBB2 and breast cancer.